Knight Therapeutics (GUD) Competitors

Tilray Brands (TSE:TLRY) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Do analysts rate TLRY or GUD?

Knight Therapeutics has a consensus price target of C$7.15, suggesting a potential upside of 12.78%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media favor TLRY or GUD?

In the previous week, Tilray Brands had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.72 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Positive
Knight Therapeutics	Neutral

Which has higher earnings & valuation, TLRY or GUD?

Knight Therapeutics has lower revenue, but higher earnings than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$821.31M	2.09	-C$183.24M	-C$2.46	-0.63
Knight Therapeutics	C$384.56M	1.64	-C$30.73M	N/A	N/A

Which has more risk & volatility, TLRY or GUD?

Tilray Brands has a beta of 3.71147, indicating that its share price is 271% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.219245, indicating that its share price is 78% less volatile than the S&P 500.

Is TLRY or GUD more profitable?

Knight Therapeutics has a net margin of -8.81% compared to Tilray Brands' net margin of -30.02%. Knight Therapeutics' return on equity of -4.04% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-30.02%	-7.24%	-1.41%
Knight Therapeutics	-8.81%	-4.04%	0.51%

Do insiders & institutionals hold more shares of TLRY or GUD?

4.7% of Tilray Brands shares are owned by institutional investors. Comparatively, 16.3% of Knight Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Knight Therapeutics beats Tilray Brands on 10 of the 16 factors compared between the two stocks.